IAVI's scientific team, drawn largely from private industry, researches and develops AIDS vaccine candidates and engages in clinical trials and research through partnerships with more than 50 academic, biotechnology, pharmaceutical and governmental institutions [REF].
In September 2009, a global group of researchers led by IAVI published a study in the journal Science identifying PG9 and PG16, two highly powerful broadly neutralizing antibodies against a wide variety of HIV variants [REF].